MedTrace Logo

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

NCT01097655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3049

Last updated 2017-05-23

Study results available
· View outcomes & findings →

Summary

The objective of this study is to observe and collect data on the usage, dosing, tolerability, and effectiveness of Kaletra (lopinavir/ritonavir) tablets in human immunodeficiency virus (HIV)-infected patients. In some patients, the study is to show the impact on tolerability of changing therapy to Kaletra tablets from other regimens.

Conditions

  • Human Immunodeficiency Virus

Sponsors & Collaborators

  • Veeda Clinical Research

    collaborator INDUSTRY

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Sandra Bloch, MD · AbbVie Deutschland GmbH & Co. KG, Medical Department

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2016-01-31
Completion
2016-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01097655 on ClinicalTrials.gov